Biotechnology

Mustang Bio

Mustang Bio released FY2026 Q1 earnings on May 5, 2026 (EST) with actual revenue of USD 0 and EPS of USD -0.1419

Mustang Bio released FY2025 Q4 earnings on March 19 (EST), actual revenue USD 0, actual EPS USD -0.0831

Mustang Bio released FY2025 annual earnings on March 19 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3913 (forecast USD -17.5)

Mustang Bio released FY2025 Q3 earnings on November 7, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.0749

Mustang Bio released FY2025 9 Months earnings on November 7, 2025 (EST), actual revenue USD 0, actual EPS USD -0.3179

Mustang Bio released FY2025 Semi-Annual earnings on August 8 (EST), actual revenue USD 0, actual EPS USD -0.2656

Mustang Bio released FY2025 Q2 earnings on August 8 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1894 (forecast USD --)

Mustang Completes Non-Dilutive Private Placement to Strengthen Financial Position

Mustang Bio Receives FDA Orphan Drug Designation, MB-101 Phase 1 Trial Shows Positive Results

Mustang Bio released FY2025 Q1 earnings on May 14 EST, with actual revenue of USD 0 and EPS of USD -0.0534

Mustang Bio released FY2024 annual earnings on March 28 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -25.8358 USD (forecast -30.5 USD)

Mustang Bio released FY2024 Q4 earnings on March 28 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.8987 (forecast USD -8)

Mustang Bio, Inc. Announces Public Offering of 2,657,807 Shares at $3.01 per Share, Aiming to Raise Approximately $8 Million

Mustang Bio released FY2024 Q3 earnings on November 8 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.9558 (forecast USD -6.5)

Mustang Bio released FY2024 9 Months Earnings on November 8 (EST), with actual revenue of USD 0 and EPS of USD -44.456

Mustang Bio released FY2024 Q2 earnings on August 13, 2024 (EST), with actual revenue of USD 0 (forecast USD 0) and actual EPS of USD -18.3592 (forecast USD -7)

Mustang Bio released FY2024 Semi-Annual Earnings on August 13 (EST), with actual revenue of 0 USD and EPS of -39.1733 USD

Mustang Bio, Inc. (MBIO) stock rises over 207%

Fortress Biotech Announces Positive Efficacy and Safety Data from Phase 1/2 Clinical Trial of MB-106 CD20-Targeted Autologous CAR-T Therapy

Mustang Bio released FY2024 Q1 earnings on May 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -24.8134 (forecast USD -11)

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Silexion Therapeutics

Micware

BiomX

Vida Global

MetaVia

MicroAlgo

Tradr 2X Long XNDU Daily ETF

MBIO

MindBio Therapeutics Corp. (CSE: MBIO) has announced its innovative approach to detecting drug and alcohol impairment using AI and voice analysis. This method aims to provide real-time, non-invasive impairment detection, addressing limitations of traditional methods like breathalyzers and blood tests. The company is developing a platform that utilizes over 50 million data points from voice recordings to accurately predict intoxication levels. This technology targets various industries, including mining, aviation, and law enforcement, and reflects a growing trend towards AI-powered diagnostics in healthcare.

Fidelity

MindBio Therapeutics Corp. (CSE: MBIO) Harnesses Key AI, Voice Analysis to Offer Impairment Solution

LABU

IBBQ

SBIO

ARKG

MindBio Therapeutics Corp. (CSE: MBIO) is advancing a novel AI-driven approach to detect drug and alcohol intoxication through voice analysis. This method aims to provide real-time, noninvasive diagnostics, addressing limitations of traditional testing methods. The company is developing an enterprise platform that integrates Edge-AI kiosks for various industries, including law enforcement and construction. MindBio's technology utilizes over 50 million data points to predict intoxication accurately, reflecting a shift towards innovative health solutions. The announcement was disseminated via BioMedWire, a communications platform focused on biotech and life sciences.

Direxion S&P Biotech Bull 3X

Invesco Nasdaq Biotechnology ETF

VG Health

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

VanEck Biotech ETF

iShares US Pharma

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

MindBio Therapeutics Corp. (CSE: MBIO) Leveraging AI, Voice Analysis to Develop Intoxication Detection

Advaita Bio has launched the iSCanGuide™, a cloud platform that integrates single-cell and spatial transcriptomics analysis using GPU acceleration. This platform transforms extensive datasets into biologically meaningful results, reducing analysis time from weeks to minutes. It unifies fragmented workflows into a single research environment, supporting real-time interactions and standardized procedures. iSCanGuide enhances reproducibility and consistency across experiments, facilitating interactive analysis and intercellular communication mapping. The platform is built on two decades of validated scientific knowledge and is trusted by over 13,000 researchers worldwide.

prnewswire

Atrium Therapeutics

10X Genomics

11:44 ETAdvaita Bio představuje iSCanGuide™: Integrovanou analýzu jednobuněčné a prostorové transkriptomiky využívající infrastrukturu s GPU akcelerací

AADI

Advaita Bio has launched iSCanGuide, a cloud-based platform designed to streamline single-cell and spatial transcriptomics analysis. This GPU-accelerated platform integrates fragmented workflows, reducing analysis time from weeks to minutes. Key features include a user-friendly interface, standardized workflows, and support for various data formats. iSCanGuide connects to Advaita's iPathwayGuide for comprehensive pathway analysis, enhancing researchers' ability to derive insights from complex datasets. The platform aims to simplify the analysis process, making it accessible for both novice and expert users.

Aadi Biosciences

iShares Global Healthcare

07:45 ETAdvaita Bio Launches iSCanGuide™: Unified Single-Cell and Spatial Transcriptomics Analysis, Powered by GPU-Accelerated Infrastructure

SONN.CVR

Creatv Bio, a cancer diagnostic blood testing company, announced one poster presentation and four poster abstracts for the 2026 ASCO Annual Meeting, scheduled for May 29-June 2, 2026, in Chicago. The presentations include studies on blood-based biomarkers for predicting progression-free survival in metastatic breast cancer and the use of the LifeTracDx® blood test in collaboration with pharmaceutical partners. The company aims to develop diagnostic tools for cancer therapies and provide continuous monitoring for optimizing treatment regimens.

MorningStar

Sonnet BioTherapeutic CVR

BriaCell Therapeutics

BRIACELL THERAPEUTICS CORP C/WTS (TO PUR COM)

BRIACELL THERAPEUTICS CORP C/WTS 26/02/2026(TO PUR COM)

CytoDyn Inc.

BRIACELL THERAPEUTICS CORP C/WTS 15/01/2031 (TO PUR  COM)

Creatv Announces Five Clinical Data Presentations at ASCO 2026

RPRX

The drug royalty market reached a record $10 billion in 2025, driven by companies like Royalty Pharma. However, the emergence of AI-driven biotech, exemplified by Converge Bio's rapid development of an improved version of the cancer antibody cetuximab in just eight hours, raises questions about the traditional financial models based on slower drug development timelines. Converge Bio's AI platform demonstrated significant improvements in binding affinity, suggesting a potential disruption in the pharmaceutical royalty landscape as AI accelerates drug design and development.

Forbes

Royalty Pharma PLC - CL

Hercules Capital

Abbvie

Hercules Cap Pref Share HCXY 6.25 10/30/33

An 8-Hour AI Result Is Testing Pharma’s $10 Billion Royalty Market